{"id":"NCT01570751","sponsor":"Novo Nordisk A/S","briefTitle":"A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin","officialTitle":"A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2014-01","completion":"2014-01","firstPosted":"2012-04-04","resultsPosted":"2015-11-18","lastUpdate":"2017-03-07"},"enrollment":145,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"insulin degludec","otherNames":[]},{"type":"DRUG","name":"insulin glargine","otherNames":[]}],"arms":[{"label":"IDeg followed by IGlar","type":"EXPERIMENTAL"},{"label":"IGlar followed by IDeg","type":"EXPERIMENTAL"}],"summary":"This trial is conducted in the United States of America (USA). The aim of the trial is to confirm the efficacy of IDeg (insulin degludec) versus IGlar (insulin glargine) in controlling glycaemia. Subjects are to continue their pre-trial metformin treatment.","primaryOutcome":{"measure":"Change From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period","timeFrame":"Week 0, week 16 of each treatment period.","effectByArm":[{"arm":"IDeg","deltaMin":-0.1,"sd":1.1},{"arm":"IGlar","deltaMin":-0.1,"sd":1.1}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":46,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["28442823","30974973"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":140},"commonTop":["Nasopharyngitis"]}}